Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
183 hedge funds and large institutions have $758M invested in Day One Biopharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 43 reducing their positions, and 33 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 43
33% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 33
26% more capital invested
Capital invested by funds: $603M → $758M (+$155M)
10% more call options, than puts
Call options by funds: $7.37M | Put options by funds: $6.69M
6% more funds holding
Funds holding: 172 → 183 (+11)
4.28% less ownership
Funds ownership: 83.57% → 79.29% (-4.3%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$21.1M |
| 2 |
JFG
Jefferies Financial Group
New York
|
+$9.37M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.76M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.09M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.6M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$28.6M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$23.8M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$15.6M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$15.4M |
DAWN Hedge Fund Activity: Q4 2025 in Review
183 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q4 2025, worth a combined $758M — up 26% from $603M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new DAWN positions and 33 closed out — a net gain of 11 holders — while 74 added to existing stakes and 43 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $21.1M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.
- 183 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q4 2025, up from 172 in Q3 2025.
- Funds reported $758M of Day One Biopharmaceuticals stock for Q4 2025, up 26% quarter-over-quarter.
- 44 funds opened new Day One Biopharmaceuticals positions in Q4 2025 and 33 closed out, a net change of +11 holders.
- The largest Day One Biopharmaceuticals buyer in Q4 2025 was Vestal Point Capital, an estimated $21.1M added.
- The largest Day One Biopharmaceuticals seller in Q4 2025 was Fidelity Investments, an estimated $36.6M sold.
Based on aggregated 13F filings for Q4 2025.